Sanofi SA EURONEXT:SAN:
SANOFI’S NEXVIAZYME MET ALL PRIMARY AND SECONDARY ENDPOINTS IN INFANTILE-ONSET POMPE DISEASE PHASE 3 STUDY
NEXVIAZYME WELL TOLERATED WITH NO SERIOUS TREATMENT-RELATED ADVERSE EVENTS IN BABY-COMET STUDY
DATA WILL SUPPORT A REGULATORY SUBMISSION FOR A LABEL EXTENSION IN US, ANTICIPATED IN SECOND HALF OF 2026
RESULTS WILL BE SHARED ON JULY 8, 2026, AT 19TH INTERNATIONAL CONGRESS ON NEUROMUSCULAR DISEASES IN FLORENCE, ITALY